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Fig. 1 Genomic agonism and phenotypic antagonism between ER and PR in breast cancer.
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Fig. 2 PR redirects ER binding to sites correlated with the binding of PR and ER/PR complexes.
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Fig. 3 Progestin stimulation remodels nucleosomes to redirect ER binding to enhancers and 
binding sites enriched for BRCA1.
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Fig. 4 Presence and activity of PR contribute to the prognostic value of ER.
Hari Singhal et al. Sci Adv 2016;2:e1501924
Published by AAAS
Fig. 5 Cytotoxic tumor regression on combination therapy with tamoxifen and PR antagonist 
CDB4124.
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